Atopic dermatitis highlights from AAD 2025 include phase 3 trial results on rocatinlimab and delgocitinib, findings on tapinarof 1% cream, and early dosing data on a new JAK1/TYK2 inhibitor.

Cibinqo is a once-daily oral pill indicated for the treatment of patients 12 years of age and older with moderate-to-severe atopic dermatitis, including the relief of pruritus (itchy skin), who ...

Patients with specific dermatological immune-mediated inflammatory diseases are not at increased risk of developing severe COVID-19.

The EU regulator has cleared Rinvoq (upadacitinib) as an oral treatment for moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older, either with or without topical ...

The US regulator has started a priority review of abrocitinib for mediate to severe atopic dermatitis in patients aged over 12, setting up a decision next April, while the EMA has also started a ...

The company will also share data demonstrating the continuous response with Nemluvio up to 56 weeks in patients with moderate-to-severe atopic dermatitis who had a partial or no response to ...

Rapid development of our pipeline products Stapokibart (CM310) (IL-4Ra antibody) Three new drug applications of Stapokibart for the treatment of moderate-to-severe atopic dermatitis (AD ...

The treatment for eczema can vary based on the type of eczema you have and how severe it is. For a typical case of atopic dermatitis, your doctor may suggest applying a moisturizer to the affected ...

Three new drug applications of Stapokibart for the treatment of moderate-to-severe atopic dermatitis (AD) in adults, chronic rhinosinusitis with nasal polyposis (CRSwNP) and seasonal allergic rhinitis ...

Background: Atopic dermatitis (AD) significantly impacts both the physical ... 46.2% being moderate, and 21.5% with severe AD. The primary caregivers were mostly first-degree family members, with 62% ...

"He is covered head to toe in dog bites, all infected," the shelter told Newsweek about the pup, now named Spartacus.